American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis.
about
Clinical outcome measures in juvenile idiopathic arthritisFinding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre studyAdvances in the treatment of polyarticular juvenile idiopathic arthritisGenome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis casesImproving care delivery and outcomes in pediatric rheumatic diseasesThe majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohortA commentary on TREAT: the trial of early aggressive drug therapy in juvenile idiopathic arthritis.The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 monthsJuvenile Idiopathic ArthritisEfficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of ChildrDisease activity and fatigue in juvenile idiopathic arthritis.Endothelial progenitor cell levels in juvenile idiopathic arthritis patients: effects of anti-inflammatory therapies.Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritisTrial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.Inactive disease and remission in childhood-onset systemic lupus erythematosusMRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.Reduced physical activity in children and adolescents with Juvenile Idiopathic Arthritis despite satisfactory control of inflammation.Subclinical cardiovascular system changes in obese patients with juvenile idiopathic arthritisMethotrexate efficacy, but not its intolerance, is associated with the dose and route of administrationDaily Sleep Patterns, Sleep Quality, and Sleep Hygiene Among Parent-Child Dyads of Young Children Newly Diagnosed With Juvenile Idiopathic Arthritis and Typically Developing Children.The PRINTO criteria for clinically inactive disease in juvenile dermatomyositisAssessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists.Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanerceptOutcomes research in childhood autoimmune diseases.A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC.Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review.Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Treatment in juvenile rheumatoid arthritis and new treatment options.Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.How common is remission in juvenile idiopathic arthritis: A systematic review.Juvenile idiopathic arthritis: what is the utility of ultrasound?Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
P2860
Q26752701-64264D6C-E17F-4116-B34A-D0F5B685E9B2Q26786198-469636A9-007F-4A77-9B41-7F895E9F3105Q27001017-F1211B00-95F4-4E5C-B167-4017BA719B6FQ30795448-98FAD452-5C8A-47B3-8EE1-AEF85141401AQ30832692-4DB833BC-E8B7-4839-B8EE-8CD45AA22BD5Q31033140-7535888E-EFAA-4E1F-A3BC-223717D28ACBQ31064321-8A5C976B-7D7C-435C-93B7-A53A3A901302Q33568429-C8530362-EBBB-489D-AF85-39E03D4AF592Q33572045-1F6678C4-028C-4938-ACF2-CC93EFB36F1BQ33659233-9BFE2205-C9C8-46F7-885B-38842CC65AF7Q33801499-9957D53F-EF35-4066-BAD7-FCFEF8C9DFB7Q33982847-61226E6F-BF6B-40FD-82DA-0A6F70673CD0Q35108691-3DA18DC8-DA88-4374-8748-1C74E41632B5Q35743755-92917956-66AC-44EC-B9DD-1D9E7055776DQ35870808-34677D47-CA86-492C-9323-CBA09A49AE56Q35911531-BC74012B-D1A3-4943-A563-C49AF8878DF2Q35926593-85EA13B2-8EBA-42C5-8179-88602A8F3E01Q36183846-19259BC7-9320-420D-92E1-28E1DB95F91CQ36266841-C23386E6-78FD-4A0D-94C4-C1E7306C8EEAQ36364223-74CA5C78-DF3A-40A3-942C-20CD38E05A18Q36716845-74661FB9-511F-487D-A8B4-365F5C203642Q37006464-CBB1E982-513D-4304-8CF8-B0ADADA7BA85Q37228166-79C5AFC2-6217-4E6E-A515-1F94EEFA8C81Q37293030-85219A92-8542-4436-90F0-CA0DE33C7B89Q37428914-4D4F7141-7699-454C-9A97-42E9D6A35753Q37518319-74E4D08A-6F46-456B-9107-2C8A6253CBCFQ37608011-62777062-423E-4383-BF91-9D814B789423Q37627929-9AD7A3E2-1AF6-4C90-9014-CADB4DA691E5Q37728461-6264B167-D68D-4BC1-8736-E5666C0F4A77Q37747792-3FD8DC8D-B7E2-4F4A-8AEB-C1BB23386C75Q38061615-04FD8280-061F-49D6-A41F-0A9F205ECC4AQ38130348-39FEB728-8E8F-4CDA-95B0-93B9D2399FE9Q38223059-DD844358-CCAF-47F7-8FCB-A9C5E713F10AQ38236298-ED33ED7E-D1AC-4709-B017-23E53E301213Q38238947-7DE5E144-8F0E-43D9-81B4-AA4DF29729C0Q38528889-4555F862-CC9A-4424-AA1D-FA958721F495Q38623183-665F8662-E810-4500-9854-93BAA59283F4Q38720413-CC7DCE28-E180-46C2-A200-CE6DF1385CE1Q38746108-5E6FFCC7-ED83-47D3-8521-BAE6ABB4C095Q38765960-A11F0B43-0614-4C27-8EF8-475B120E5C1E
P2860
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
American College of Rheumatolo ...... juvenile idiopathic arthritis.
@en
American College of Rheumatolo ...... juvenile idiopathic arthritis.
@nl
type
label
American College of Rheumatolo ...... juvenile idiopathic arthritis.
@en
American College of Rheumatolo ...... juvenile idiopathic arthritis.
@nl
prefLabel
American College of Rheumatolo ...... juvenile idiopathic arthritis.
@en
American College of Rheumatolo ...... juvenile idiopathic arthritis.
@nl
P2093
P2860
P356
P1476
American College of Rheumatolo ...... juvenile idiopathic arthritis.
@en
P2093
Carol A Wallace
Childhood Arthritis Rheumatology Research Alliance
Edward H Giannini
Lukasz Itert
Pediatric Rheumatology Collaborative Study Group
P2860
P304
P356
10.1002/ACR.20497
P577
2011-07-01T00:00:00Z